TY - JOUR
T1 - Community concerns about genetic discrimination in life insurance persist in Australia
T2 - A survey of consumers offered genetic testing
AU - Tiller, Jane
AU - Bakshi, Andrew
AU - Dowling, Grace
AU - Keogh, Louise
AU - McInerney-Leo, Aideen
AU - Barlow-Stewart, Kristine
AU - Boughtwood, Tiffany
AU - Gleeson, Penny
AU - Delatycki, Martin B.
AU - Winship, Ingrid
AU - Otlowski, Margaret
AU - Lacaze, Paul
N1 - Funding Information:
The project is supported by a grant from the Australian Government’s Medical Research Future Fund (MRFF), ref 76721. AML is funded by a National Health and Medical Research Council (NHMRC) Early Career Fellowship (ID 1158111). PL is supported by a National Heart Foundation Future Leader Fellowship (ID 102604). Open Access funding enabled and organized by CAUL and its Member Institutions.
Funding Information:
The Australian Genetics and Life Insurance Moratorium: Monitoring the Effectiveness and Response (A-GLIMMER) study [] was funded by the Australian Medical Research Future Fund Genomics Health Futures Mission in 2020 to monitor the effectiveness of the FSC moratorium by conducting research with four different stakeholder groups - consumers, health professionals, researchers and the financial services industry []. The present study was designed to ascertain updated views and experiences of Australian consumers who have had, or been offered, genetic testing for adult-onset conditions. The study was limited to adult-onset conditions because different considerations arise in the context of predictive testing of unaffected individuals for genetic risk of future disease, compared with diagnostic testing of individuals who already have symptoms or clinical diagnosis of disease. The FSC moratorium clearly indicates that it can use disease diagnoses (whether diagnosed through clinical or geniting testing) as a basis for discrimination, but that the moratorium applies to predictive genetic tests in applications below the financial limits. The moratorium protections do not apply to individuals with childhood-onset disease, who have already received a diagnosis by the time they apply for life insurance in adulthood.
Publisher Copyright:
© 2023, The Author(s).
PY - 2024/3
Y1 - 2024/3
N2 - Fears of genetic discrimination in life insurance continue to deter some Australians from genetic testing. In July 2019, the life insurance industry introduced a partial, self-regulated moratorium restricting the use of genetic results in underwriting, applicable to policies up to certain limits (eg AUD$500,000 for death cover). We administered an online survey to consumers who had taken, or been offered, clinical genetic testing for adult-onset conditions, to gather views and experiences about the moratorium and the use of genetic results in life insurance, including its regulation. Most respondents (n = 367) had undertaken a genetic test (89%), and had a positive test result (76%; n = 243/321). Almost 30% (n = 94/326) reported testing after 1 July 2019. Relatively few respondents reported knowing about the moratorium (16%; n = 54/340) or that use of genetic results in life insurance underwriting is legal (17%; n = 60/348). Only 4% (n = 14/350) consider this practice should be allowed. Some respondents reported ongoing difficulties accessing life insurance products, even after the moratorium. Further, discrimination concerns continue to affect some consumers’ decision-making about having clinical testing and applying for life insurance products, despite the Moratorium being in place. Most respondents (88%; n = 298/340) support the introduction of legislation by the Australian government to regulate this issue. Despite the introduction of a partial moratorium in Australia, fears of genetic discrimination persist, and continue to deter people from genetic testing. Consumers overwhelmingly consider life insurers should not be allowed to use genetic results in underwriting, and that federal legislation is required to regulate this area.
AB - Fears of genetic discrimination in life insurance continue to deter some Australians from genetic testing. In July 2019, the life insurance industry introduced a partial, self-regulated moratorium restricting the use of genetic results in underwriting, applicable to policies up to certain limits (eg AUD$500,000 for death cover). We administered an online survey to consumers who had taken, or been offered, clinical genetic testing for adult-onset conditions, to gather views and experiences about the moratorium and the use of genetic results in life insurance, including its regulation. Most respondents (n = 367) had undertaken a genetic test (89%), and had a positive test result (76%; n = 243/321). Almost 30% (n = 94/326) reported testing after 1 July 2019. Relatively few respondents reported knowing about the moratorium (16%; n = 54/340) or that use of genetic results in life insurance underwriting is legal (17%; n = 60/348). Only 4% (n = 14/350) consider this practice should be allowed. Some respondents reported ongoing difficulties accessing life insurance products, even after the moratorium. Further, discrimination concerns continue to affect some consumers’ decision-making about having clinical testing and applying for life insurance products, despite the Moratorium being in place. Most respondents (88%; n = 298/340) support the introduction of legislation by the Australian government to regulate this issue. Despite the introduction of a partial moratorium in Australia, fears of genetic discrimination persist, and continue to deter people from genetic testing. Consumers overwhelmingly consider life insurers should not be allowed to use genetic results in underwriting, and that federal legislation is required to regulate this area.
UR - http://www.scopus.com/inward/record.url?scp=85159097440&partnerID=8YFLogxK
U2 - 10.1038/s41431-023-01373-1
DO - 10.1038/s41431-023-01373-1
M3 - Article
C2 - 37169978
AN - SCOPUS:85159097440
SN - 1018-4813
VL - 32
SP - 286
EP - 294
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 3
ER -